Alnylam to Present Five-Year HELIOS-B Data and Expanding Evidence on the Benefits of RNAi-Powered TTR Silencing with AMVUTTRA® (vutrisiran) at AHA and ISA 2026
Alnylam will present five-year data from the HELIOS-B Phase 3 study of AMVUTTRA (vutrisiran) at AHA and ISA 2026, showing long-term benefits in treating transthyretin amyloidosis (ATTR). The study includes open-label extension data and post hoc analyses demonstrating preserved exercise capacity and cardiopulmonary performance. Additional real-world evidence and comparisons with other treatments will also be presented.
How this was made
The 30-second read
Why it matters
The five-year data provide the most extensive efficacy and safety evidence to date, potentially influencing FDA considerations and payer coverage.
Market read
First report of long-term trial outcomes; could drive short-term price movement and inform longer-term valuation.
What to watch
Reimbursement decisions and competition from other ATTR therapies could limit upside even with positive data.
Background
Alnylam (ALNY) is a leading RNAi therapeutics company; its drug AMVUTTRA (vutrisiran) targets transthyretin amyloidosis.
Ticker impact
Alnylam will present five-year HELIOS-B Phase 3 data and new long-term results for vutrisiran at AHA and ISA 2026.
likely upward pressure as market incorporates favorable efficacy data.
First disclosure of five-year extension results; historically, positive late-breaking data moves biotech stocks.
Market effects
Strengthens confidence in RNAi therapeutics and may lift peer biotech stocks developing similar modalities.
US biotech sector could see modest gains; European and Asian RNAi developers may benefit indirectly.
Highlights progress in treating ATTR amyloidosis, a niche but growing therapeutic area worldwide.
Counterpoint
If the data show only modest benefit or safety concerns, the stock could face disappointment despite hype.
Key entities
- CompanyAlnylam Pharmaceuticals
US-listed biotech developing RNAi drugs, ticker ALNY.
- DrugAMVUTTRA (vutrisiran)
RNAi therapeutic for ATTR-CM and hATTR-PN.
